Alnylam Pharmaceuticals (ALNY) FDA Approvals

Alnylam Pharmaceuticals logo
$145.04 -2.78 (-1.88%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Alnylam Pharmaceuticals (ALNY). Over the past two years, Alnylam Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Cemdisiran, Vutrisiran, ALN-HTT02, Vutrisiran, Zilebesiran, Fitusiran, and GIVLAARI. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Cemdisiran FDA Regulatory Events

Cemdisiran is a drug developed by Alnylam Pharmaceuticals for the following indication: Immunoglobulin A Nephropathy (IgAN). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Vutrisiran FDA Regulatory Timeline and Events

Vutrisiran is a drug developed by Alnylam Pharmaceuticals for the following indication: For the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

ALN-HTT02 FDA Regulatory Events

ALN-HTT02 is a drug developed by Alnylam Pharmaceuticals for the following indication: in Huntington’s Disease. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Vutrisiran (HELIOS-B) FDA Regulatory Timeline and Events

Vutrisiran (HELIOS-B) is a drug developed by Alnylam Pharmaceuticals for the following indication: Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Zilebesiran (ALN-AGT) FDA Regulatory Events

Zilebesiran (ALN-AGT) is a drug developed by Alnylam Pharmaceuticals for the following indication: Mild-to-Moderate Hypertension. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Fitusiran FDA Regulatory Events

Fitusiran is a drug developed by Alnylam Pharmaceuticals for the following indication: Hemophilia A or B. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

GIVLAARI FDA Regulatory Events

GIVLAARI is a drug developed by Alnylam Pharmaceuticals for the following indication: Acute Hepatic Porphyria (AHP). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Alnylam Pharmaceuticals FDA Events - Frequently Asked Questions

In the past two years, Alnylam Pharmaceuticals (ALNY) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Alnylam Pharmaceuticals (ALNY) has reported FDA regulatory activity for the following drugs: Vutrisiran (HELIOS-B), Vutrisiran, Cemdisiran, Zilebesiran (ALN-AGT), ALN-HTT02, Fitusiran and GIVLAARI.

The most recent FDA-related event for Alnylam Pharmaceuticals occurred on November 19, 2026, involving Cemdisiran. The update was categorized as "FDA approved," with the company reporting: "Alnylam Pharmaceuticals, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran), an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive."

Current therapies from Alnylam Pharmaceuticals in review with the FDA target conditions such as:

  • Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy - Vutrisiran (HELIOS-B)
  • For the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. - Vutrisiran
  • Immunoglobulin A Nephropathy (IgAN) - Cemdisiran
  • Mild-to-Moderate Hypertension - Zilebesiran (ALN-AGT)
  • in Huntington’s Disease - ALN-HTT02
  • Hemophilia A or B - Fitusiran
  • Acute Hepatic Porphyria (AHP) - GIVLAARI
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:ALNY last updated on 11/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners